Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Apr 1;45(13):1173-1176.
doi: 10.1093/eurheartj/ehad889.

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

Neila Sayah  1 , Deepak L Bhatt  2 , Michael Miller  3 , Eliot A Brinton  4 , Terry A Jacobson  5 , Steven B Ketchum  6 , Lixia Jiao  6 , Armando Lira Pineda  6 , Ralph T Doyle Jr  6 , Jean Claude Tardif  7 , Christie M Ballantyne  8 , Ph Gabriel Steg  1   9
Affiliations
Randomized Controlled Trial

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

Neila Sayah et al. Eur Heart J. .
No abstract available

Keywords: Acute coronary syndrome; Clinical trials; Icosapent ethyl; Ischaemic events.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) First and subsequent events for the primary composite outcome in patients with recent ACS. (B) Cumulative incidence curves of the primary composite outcome in patients with recent ACS
See this image and copyright information in PMC

References

    1. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11–22. 10.1056/NEJMoa1812792 - DOI - PubMed
    1. Gaba P, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, et al. Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction. J Am Coll Cardiol 2022;79:1660–71. 10.1016/j.jacc.2022.02.035 - DOI - PubMed
    1. Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol 2017;40:138–48. 10.1002/clc.22692 - DOI - PMC - PubMed
    1. Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, et al. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses. Circulation 2021;143:33–44. 10.1161/CIRCULATIONAHA.120.050276 - DOI - PMC - PubMed
    1. Bhatt RD, Libby P, Verma S, Mason RP, Bhatt DL. The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization. Prog Cardiovasc Dis 2021;69:3–10. 10.1016/j.pcad.2021.08.003 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources